SCHEMBL16795241

SCHEMBL16795241

Cc1c(O)nc(-c2cnn3ccccc23)nc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.50
JAK2 O60674 10/20 0.41
JAK1 P23458 10/20 0.41
JAK3 P52333 10/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
CCNK O75909 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
PIK3CB P42338 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CAMKK1 Q8N5S9 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795169 0.85 DYRK1A (0.47) DYRK1AJAK2JAK1JAK3CCNK
SCHEMBL18302287 0.84 DYRK1A (0.49) DYRK1AJAK2JAK1JAK3NPC1
SCHEMBL16795294 0.82 DYRK1A (0.50) DYRK1AJAK2JAK1JAK3NPC1
SCHEMBL2348287 0.78 DYRK1A (0.44) DYRK1AJAK2JAK1JAK3NPC1
SCHEMBL2350432 0.78 CDK2 (0.44) DYRK1AJAK2JAK1JAK3CCNK
SCHEMBL18302112 0.75 DYRK1A (0.49) DYRK1AJAK2JAK1JAK3NPC1
SCHEMBL2230967 0.75 DYRK1A (0.52) DYRK1AJAK2JAK1JAK3NPC1
SCHEMBL16796062 0.74 DYRK1A (0.54) DYRK1AJAK2JAK1JAK3NPC1
SCHEMBL16795290 0.73 DYRK1A (0.47) DYRK1AJAK2JAK1JAK3CCNK
SCHEMBL15181320 0.71 DYRK1A (0.51) DYRK1AJAK2JAK1JAK3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759793-B2 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors ALMIRALL, S.A. (ES) 2020-09-01 US disclosed
US-20180162856-A1 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2018-06-14 US disclosed
EP-3307272-A1 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS Almirall, S.A. (ES) 2018-04-18 EP disclosed
WO-2016198663-A1 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2016-12-15 WO disclosed
WO-2015086693-A1 PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162856-A1 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS JAK2, JAK3, JAK1 DYRK1A 443/4885JAK2 1/4885JAK1 3/4885
US-10759793-B2 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors JAK2, JAK3, JAK1 DYRK1A 443/4885JAK2 1/4885JAK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.